诺华制药
NVS156.420USD
+2.360+1.53%
收盘 02/06, 16:00（美东）报价延迟15分钟
300.14B总市值
21.69市盈率 TTM
关于 诺华制药 公司
诺华公司为瑞士总部的全球制药巨头，专注创新处方药的研发、制造与行销。公司现以单一 创新药物 部门运营，聚焦免疫、肿瘤、神经、心血管、肾脏及代谢等治疗领域，并运用数字平台加速临床与商业决策。此前属下的仿制药与生物仿制药业务已分拆为独立公司 Sandoz，因此诺华资源得以全面投入先进疗法与下一代技术平台。
诺华制药简介
公司代码NVS
公司名称Novartis AG
上市日期May 07, 2001
CEONarasimhan (Vasant)
员工数量75883
证券类型Depository Receipt
年结日May 07
公司地址Lichtstrasse 35
城市BASEL
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家Switzerland
邮编4056
电话41613241111
网址https://www.novartis.com/
公司代码NVS
上市日期May 07, 2001
CEONarasimhan (Vasant)
诺华制药公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Harry Kirsch
Mr. Harry Kirsch
Chief Financial Officer, Member of the Executive Committee
Chief Financial Officer, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Vasant (Vas) Narasimhan, M.D.
Dr. Vasant (Vas) Narasimhan, M.D.
Chief Executive Officer, Member of the Executive Committee
Chief Executive Officer, Member of the Executive Committee
--
--
Mr. Frans van Houten
Mr. Frans van Houten
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Steffen Lang, Ph.D.
Dr. Steffen Lang, Ph.D.
President - Operations, Member of the Executive Committee
President - Operations, Member of the Executive Committee
--
--
Mr. Patrice Bula
Mr. Patrice Bula
Non-Executive Lead Independent Director
Non-Executive Lead Independent Director
--
--
Ms. Bridgette P. Heller
Ms. Bridgette P. Heller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Harry Kirsch
Mr. Harry Kirsch
Chief Financial Officer, Member of the Executive Committee
Chief Financial Officer, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Vasant (Vas) Narasimhan, M.D.
Dr. Vasant (Vas) Narasimhan, M.D.
Chief Executive Officer, Member of the Executive Committee
Chief Executive Officer, Member of the Executive Committee
--
--
收入明细
单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Rest of portfolio
2.56B
18.40%
Cardiovascular, Renal and Metabolism - Entresto
1.88B
13.49%
Immunology - Cosentyx
1.70B
12.21%
Oncology -Kisqali
1.33B
9.55%
Neuroscience - Kesimpta
1.22B
8.79%
其他
5.22B
37.56%
地区USD
名称
营收
占比
US
6.04B
43.40%
Europe
4.25B
30.56%
Asia / Africa / Australasia
2.67B
19.17%
Canada and Latin America
956.00M
6.87%
业务
地区
业务USD
名称
营收
占比
Rest of portfolio
2.56B
18.40%
Cardiovascular, Renal and Metabolism - Entresto
1.88B
13.49%
Immunology - Cosentyx
1.70B
12.21%
Oncology -Kisqali
1.33B
9.55%
Neuroscience - Kesimpta
1.22B
8.79%
其他
5.22B
37.56%
股东统计
更新时间: 2月1日 周日
更新时间: 2月1日 周日
持股股东
股东类型
持股股东
持股股东
占比
Dodge & Cox
0.55%
PRIMECAP Management Company
0.49%
Dimensional Fund Advisors, L.P.
0.46%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.30%
其他
97.83%
持股股东
持股股东
占比
Dodge & Cox
0.55%
PRIMECAP Management Company
0.49%
Dimensional Fund Advisors, L.P.
0.46%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.30%
其他
97.83%
股东类型
持股股东
占比
Investment Advisor
3.37%
Investment Advisor/Hedge Fund
2.86%
Research Firm
0.48%
Hedge Fund
0.20%
Bank and Trust
0.13%
Pension Fund
0.03%
Family Office
0.02%
其他
92.91%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
2023
135.99M
7.08%
-9.78M
2025Q3
1967
135.58M
7.06%
-11.39M
2025Q2
1941
140.71M
7.27%
+2.13M
2025Q1
1953
141.07M
7.20%
+870.45K
2024Q4
1926
134.00M
6.78%
-9.24M
2024Q3
1858
134.89M
6.74%
-11.71M
2024Q2
1840
139.20M
6.87%
-9.16M
2024Q1
1808
141.30M
6.92%
-7.93M
2023Q4
1811
141.99M
6.94%
-15.97M
2023Q3
1775
150.92M
7.33%
-7.18M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Dodge & Cox
10.59M
0.55%
-62.48K
-0.59%
Sep 30, 2025
PRIMECAP Management Company
9.34M
0.49%
-1.06M
-10.19%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
8.84M
0.46%
-220.21K
-2.43%
Sep 30, 2025
Fisher Investments
7.24M
0.38%
+117.95K
+1.66%
Sep 30, 2025
Loomis, Sayles & Company, L.P.
5.66M
0.3%
+83.33K
+1.49%
Sep 30, 2025
Franklin Mutual Advisers, LLC
3.98M
0.21%
-184.68K
-4.44%
Sep 30, 2025
Morgan Stanley Smith Barney LLC
3.68M
0.19%
+29.41K
+0.81%
Sep 30, 2025
Parametric Portfolio Associates LLC
3.19M
0.17%
+113.80K
+3.70%
Sep 30, 2025
Managed Account Advisors LLC
3.04M
0.16%
+120.48K
+4.13%
Sep 30, 2025
Aperio Group, LLC
2.45M
0.13%
+205.41K
+9.16%
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
VanEck Pharmaceutical ETF
19.83%
Amplify International Enhanced Dividend Income ETF
3.67%
Abacus FCF International Leaders ETF
3.41%
Altrius Global Dividend ETF
2.39%
Invesco International Dividend Achievers ETF
2.08%
Freedom Day Dividend ETF
2.03%
Fundamentals First ETF
1.91%
SP Funds S&P World (ex-US) ETF
1.56%
DFA Dimensional Internatl High Profitability ETF
1.54%
Avantis Responsible International Equity ETF
1.35%
查看更多
VanEck Pharmaceutical ETF
占比19.83%
Amplify International Enhanced Dividend Income ETF
占比3.67%
Abacus FCF International Leaders ETF
占比3.41%
Altrius Global Dividend ETF
占比2.39%
Invesco International Dividend Achievers ETF
占比2.08%
Freedom Day Dividend ETF
占比2.03%
Fundamentals First ETF
占比1.91%
SP Funds S&P World (ex-US) ETF
占比1.56%
DFA Dimensional Internatl High Profitability ETF
占比1.54%
Avantis Responsible International Equity ETF
占比1.35%
分红派息
近5年累计派现
29.75B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Feb 20, 2025
NVS.NB Final Cash Dividend of gross USD 3.99399 paid on Apr 25, 2025 going ex on Mar 12, 2025
Mar 12, 2025
Apr 25, 2025
Mar 12, 2025
Feb 12, 2024
NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Apr 19, 2024
Mar 07, 2024
Feb 02, 2023
NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 20, 2023
Mar 09, 2023
Feb 04, 2022
NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022
Mar 09, 2022
Mar 17, 2022
Mar 08, 2022
Jan 26, 2021
NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021
Mar 05, 2021
Mar 15, 2021
Mar 04, 2021
Jan 31, 2020
NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020
Mar 04, 2020
Mar 12, 2020
Mar 03, 2020
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
